Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Infect Dis ; 213(7): 1180-8, 2016 Apr 01.
Article in English | MEDLINE | ID: mdl-26597256

ABSTRACT

BACKGROUND: Severe H1N1 influenza can be lethal in otherwise healthy individuals and can have features of reactive hemophagocytic lymphohistiocytosis (HLH). HLH is associated with mutations in lymphocyte cytolytic pathway genes, which have not been previously explored in H1N1 influenza. METHODS: Sixteen cases of fatal influenza A(H1N1) infection, 81% with histopathologic hemophagocytosis, were identified and analyzed for clinical and laboratory features of HLH, using modified HLH-2004 and macrophage activation syndrome (MAS) criteria. Fourteen specimens were subject to whole-exome sequencing. Sequence alignment and variant filtering detected HLH gene mutations and potential disease-causing variants. Cytolytic function of the PRF1 p.A91V mutation was tested in lentiviral-transduced NK-92 natural killer (NK) cells. RESULTS: Despite several lacking variables, cases of influenza A(H1N1) infection met 44% and 81% of modified HLH-2004 and MAS criteria, respectively. Five subjects (36%) carried one of 3 heterozygous LYST mutations, 2 of whom also possessed the p.A91V PRF1 mutation, which was shown to decrease NK cell cytolytic function. Several patients also carried rare variants in other genes previously observed in MAS. CONCLUSIONS: This cohort of fatal influenza A(H1N1) infections confirms the presence of hemophagocytosis and HLH pathology. Moreover, the high percentage of HLH gene mutations suggests they are risk factors for mortality among individuals with influenza A(H1N1) infection.


Subject(s)
Exome , Genetic Predisposition to Disease , Influenza A Virus, H1N1 Subtype , Influenza, Human/genetics , Lymphohistiocytosis, Hemophagocytic/genetics , Macrophage Activation Syndrome/genetics , Cohort Studies , Female , Genotype , HEK293 Cells , Humans , Influenza, Human/mortality , Killer Cells, Natural/physiology , Male , Mutation , Perforin/genetics , Perforin/metabolism , Sequence Analysis, DNA
2.
Wound Repair Regen ; 16(1): 117-24, 2008.
Article in English | MEDLINE | ID: mdl-18211583

ABSTRACT

MDI 301 is a picolinic acid-substituted ester of 9-cis retinoic acid. It has been shown in the past that MDI 301 increases epidermal thickness, decreases matrix metalloproteinase (MMP) activity, and increases procollagen synthesis in organ-cultured human skin. Unlike all-trans retinoic acid (RA), MDI 301 does not induce expression of proinflammatory cytokines or induce expression of leukocyte adhesion molecules in human skin. In the present study we examined topical MDI 301 treatment for ability to improve the structure and function of skin in three models of skin damage in rodents and for ability to improve abrasion wound healing in these models. MDI 301 was applied daily to the skin of rats treated with the potent corticosteroid, clobetasol propionate, to the skin of diabetic rats (8 weeks posttreatment with streptozotocin) and to the skin of aged (14-16-month-old) rats. In all three models, subsequently induced abrasion wounds healed more rapidly in the retinoid-treated animals than in vehicle-treated controls. Immediately after complete wound closure, tissue from the wound site (as well as from a control site) was put into organ culture and maintained for 3 days. At the end of the incubation period, culture fluids were assessed for soluble type I collagen and for MMPs-2 and -9. In all three models, the level of type I collagen was increased and MMP levels were decreased by MDI 301. In all three models, skin irritation during the retinoid-treatment phase was virtually nonexistent.


Subject(s)
Retinoids/pharmacology , Skin Diseases/physiopathology , Skin/drug effects , Wound Healing/drug effects , Animals , Atrophy , Collagen Type I/analysis , Dermatologic Agents/pharmacology , Disease Models, Animal , Male , Matrix Metalloproteinases/analysis , Mice , Mice, Hairless , Rats , Rats, Hairless , Skin/chemistry , Skin/pathology , Skin Aging , Skin Diseases/chemically induced , Skin Diseases/drug therapy , Skin Diseases/etiology
3.
J Pharmacol Exp Ther ; 324(3): 938-47, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18055879

ABSTRACT

7-Chloro-5-(4-hydroxyphenyl)-1-methyl-3-(naphthalen-2-ylmethyl)-4,5-dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one (Bz-423) is a benzodiazepine that has cytotoxic and cytostatic activity against a variety of cells in vivo and in vitro. In the present study, we demonstrate that Bz-423 (formulated for topical delivery) reduces epidermal hyperplasia in human psoriatic skin after transplantation to severe, combined immunodeficient (scid) mice. Bz-423 also suppresses the hyperplasia that develops in nonpsoriatic human skin as a consequence of transplantation to scid mice. Proliferation of human epidermal keratinocytes in monolayer culture was suppressed by Bz-423 at concentrations of 0.5 to 2.0 muM (noncytotoxic concentrations). Keratinocyte growth inhibition was accompanied by increased oxidant generation in Bz-423-treated cells, and treatment with vitamin E along with Bz-423 reversed the growth inhibition. Growth inhibition was accompanied by a redistribution of beta-catenin from a cytoplasmic pool to the cell membrane and by reduced levels of c-myc and cyclin D1 (two molecules associated with Wnt pathway signaling). Several analogs of Bz-423 were examined for antiproliferative activity against human epidermal keratinocytes and human dermal fibroblasts in monolayer culture. Each of the analogs tested suppressed growth of both cell types, but in all cases, keratinocytes were more sensitive than fibroblasts. Two of the compounds were found to suppress epidermal hyperplasia induced with all-trans retinoic acid in organ cultures of human skin. Taken together, these data show that Bz-423 and certain analogs produce biological responses in skin cells in vitro and in vivo that are consistent with therapeutic goals for treating psoriasis or epidermal hyperplasia resulting from other causes.


Subject(s)
Benzodiazepines/therapeutic use , Disease Models, Animal , Keratinocytes/cytology , Psoriasis/drug therapy , Severe Combined Immunodeficiency/drug therapy , Skin Transplantation , Animals , Benzodiazepines/pharmacology , Cell Proliferation/drug effects , Humans , Keratinocytes/drug effects , Mice , Mice, SCID , Psoriasis/pathology , Severe Combined Immunodeficiency/pathology , Skin Transplantation/immunology , Skin Transplantation/methods
4.
Arch Dermatol Res ; 300(1): 27-35, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17968574

ABSTRACT

Mice on a calorie-restricted (CR) diet (total calories restricted to 70% of ad libitum; AL) for periods of time ranging from 3 to 18 months were examined for response to topical treatment with all-trans retinoic acid (RA). Daily application of a 0.1% solution of RA to the shaved skin of UM-HET3 mice on an AL diet produced a severe irritation that was evident by day 4, maximal at day 7-8 and still detectable at day 14. Skin irritation was characterized by redness, dryness, flaking and failure of the hair to grow at the treated site. In CR mice, the same treatment produced little detectable irritation. Animals were sacrificed at the end of the retinoid-treatment period (day 7 or day 14) and skin from these animals was examined histologically. In both AL and CR mice, a similar degree of epidermal hyperplasia was observed. Numerous inflammatory cells (mononuclear cells and granulocytes) were present in the skin of both groups. Occasional S100-positive cells (presumably Langerhans cells) were also observed in the epidermis of skin from both groups. S100-positive cells were also observed in the dermis. When skin from CR and AL mice was incubated in organ culture for 3 days (on day 7 after initiation of RA treatment), similar levels of four different pro-inflammatory cytokines were found in the conditioned medium. Soluble type I collagen levels were also similar. In contrast, the level of matrix metalloproteinase-9 was lower in the conditioned medium of skin from CR mice than in conditioned medium from skin cultures of AL mice. Taken together, these studies suggest that CR may provide a way to mitigate the irritation that normally accompanies RA treatment without compromising the beneficial effects of retinoid use. CR appears to exert a protective effect at the target tissue level rather than by a reduction in pro-inflammatory events, per se.


Subject(s)
Caloric Restriction , Dermatitis, Irritant/etiology , Dermatitis, Irritant/prevention & control , Keratolytic Agents/adverse effects , Tretinoin/adverse effects , Administration, Topical , Animals , Cell Proliferation/drug effects , Collagen/metabolism , Collagen Type I , Cytokines/metabolism , Dermatitis, Irritant/pathology , Female , Keratolytic Agents/administration & dosage , Keratolytic Agents/pharmacology , Male , Matrix Metalloproteinase 9/metabolism , Mice , Mice, Inbred Strains , Organ Culture Techniques , S100 Proteins/metabolism , Skin/drug effects , Skin/metabolism , Skin/pathology , Time Factors , Tretinoin/administration & dosage , Tretinoin/pharmacology
5.
Proc Natl Acad Sci U S A ; 104(35): 13996-4001, 2007 Aug 28.
Article in English | MEDLINE | ID: mdl-17715297

ABSTRACT

The zebrafish is a powerful model for studying vascular development, demonstrating remarkable conservation of this process with mammals. Here, we identify a zebrafish mutant, redhead (rhd(mi149)), that exhibits embryonic CNS hemorrhage with intact gross development of the vasculature and normal hemostatic function. We show that the rhd phenotype is caused by a hypomorphic mutation in p21-activated kinase 2a (pak2a). PAK2 is a kinase that acts downstream of the Rho-family GTPases CDC42 and RAC and has been implicated in angiogenesis, regulation of cytoskeletal structure, and endothelial cell migration and contractility among other functions. Correction of the Pak2a-deficient phenotype by Pak2a overexpression depends on kinase activity, implicating Pak2 signaling in the maintenance of vascular integrity. Rescue by an endothelial-specific transgene further suggests that the hemorrhage seen in Pak2a deficiency is the result of an autonomous endothelial cell defect. Reduced expression of another PAK2 ortholog, pak2b, in Pak2a-deficient embryos results in a more severe hemorrhagic phenotype, consistent with partially overlapping functions for these two orthologs. These data provide in vivo evidence for a critical function of Pak2 in vascular integrity and demonstrate a severe disease phenotype resulting from loss of Pak2 function.


Subject(s)
Cerebral Hemorrhage/genetics , Mutation , Protein Serine-Threonine Kinases/genetics , Zebrafish/genetics , Alternative Splicing , Animals , Cerebral Hemorrhage/embryology , Cerebrovascular Circulation/genetics , Chromosome Mapping , Embryo, Nonmammalian , Genes, Recessive , Genetic Variation , Polymorphism, Restriction Fragment Length , Protein Serine-Threonine Kinases/deficiency , RNA/genetics , Reverse Transcriptase Polymerase Chain Reaction , Transcription, Genetic , Zebrafish Proteins/genetics , p21-Activated Kinases
6.
Int J Cancer ; 121(7): 1455-62, 2007 Oct 01.
Article in English | MEDLINE | ID: mdl-17557293

ABSTRACT

An siRNA directed against the extracellular calcium-sensing receptor (CaSR) was used to down-regulate this protein in CBS colon carcinoma cells. In additional studies, we utilized a variant of the parental CBS line that demonstrates CaSR expression but does not upregulate this protein in response to extracellular Ca(2+). In neither the siRNA-transfected cells nor the Ca(2+)-nonresponsive variant cells did inclusion of Ca(2+) in the culture medium inhibit proliferation or induce morphological alterations. Extracellular Ca(2+) also failed to induce E-cadherin production or a shift in beta-catenin from the cytoplasm to the cell membrane. In mock-transfected cells and in a Ca(2+)-responsive variant line derived from the same parental CBS cells, Ca(2+) treatment resulted in growth-reduction. This was accompanied by increased E-cadherin production and a shift in beta-catenin distribution from the cytoplasm to the cell membrane. Additionally, down-regulation of c-myc and cyclin D1 expression was observed in mock-transfected cells and in the Ca(2+)-responsive variant line (along with reduced T cell factor transcriptional activation). Neither c-myc nor cyclin D1 was significantly down-regulated in the siRNA-transfected cells or in the Ca(2+)-nonresponsive variant cells upon Ca(2+) stimulation. In histological sections of human colon carcinoma CaSR was significantly reduced as compared to the level in normal colonic crypt epithelial cells. Where CaSR expression was high, strong surface staining for E-cadherin and beta-catenin was observed. Where CaSR expression was reduced, beta-catenin surface expression was likewise reduced.


Subject(s)
Cadherins/metabolism , Calcium/pharmacology , Receptors, Calcium-Sensing/physiology , beta Catenin/metabolism , Cell Line, Tumor , Cell Proliferation/drug effects , Colonic Neoplasms/metabolism , Colonic Neoplasms/pathology , Humans , Immunohistochemistry , Microscopy, Confocal , Microscopy, Fluorescence , RNA, Small Interfering/genetics , Receptors, Calcium-Sensing/genetics , Receptors, Calcium-Sensing/metabolism , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...